Share Twitter LinkedIn Facebook Email Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel, Comprehensive Cancer Center, Johns Hopkins University, Discusses Phase I Study Of Gilteritinib. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com Advertisement
Joe Biden Prostate Cancer Timeline: When Did It Begin? Experts Weigh In Acute Myelogenous Leukemia 4 Mins Read
Transforming AML Treatment: The Breakthrough Precision and Speed of Dr. Gabriel Mannis, MD on the Notable Platform Acute Myelogenous Leukemia 1 Min Read